Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Nanologica AB ( (SE:NICA) ) just unveiled an announcement.
Nanologica AB has completed a fully subscribed rights issue of approximately SEK 82.5 million, after a subscription period that saw 63.3 percent taken up by existing and other shareholders, with the remainder covered by underwriting commitments. The capital raise substantially enlarges the company’s share base to 328,769,846 shares following this and a recently resolved directed issue, implying significant dilution for existing shareholders while bolstering the balance sheet.
A large portion of the issue, about SEK 48.8 million, will be used to offset all outstanding loans from major shareholder Flerie Invest AB, converting debt into equity and improving Nanologica’s financial position. The transaction, which entails estimated total costs of SEK 6.5 million for the rights and directed issues, strengthens the company’s funding and reduces leverage, potentially enhancing financial flexibility for future operations within its niche life science market.
The most recent analyst rating on (SE:NICA) stock is a Sell with a SEK0.32 price target. To see the full list of analyst forecasts on Nanologica AB stock, see the SE:NICA Stock Forecast page.
More about Nanologica AB
Nanologica AB is a Swedish life science company specializing in advanced materials for pharmaceutical applications. The company focuses on developing and commercializing silica-based products used in drug delivery and chromatography, serving biotech and pharma customers seeking improved formulation and purification solutions.
Average Trading Volume: 198,621
Technical Sentiment Signal: Sell
Current Market Cap: SEK103.1M
Find detailed analytics on NICA stock on TipRanks’ Stock Analysis page.